The three global study partners to the DAWN2 study are the International Diabetes Federation (IDF), International Alliance of Patient Organisations (IAPO), and the Steno Diabetes Center. Together with Novo Nordisk, these partners oversee and work in partnership to support the study execution, dissemination and translation.
Information about each of these global partner organisations are provided below.
The International Diabetes Federation (IDF) is an umbrella organisation of more than 200 national diabetes associations in more than 160 countries. It represents the interests of the growing number of people with diabetes and those at risk of developing the condition. The Federation has been leading the global diabetes community since 1950.
IDF is the global advocate for the more than 371 million people with diabetes worldwide as well as their families and healthcare providers. IDF has official relations with the World Health Organization and is also associated with the Department of Public Information of the United Nations.
To ensure the best possible communication between the different working bodies of IDF and its member associations, each association is assigned to one of seven IDF regions.
The principal aims of the IDF regions are: to bring local needs and activities to the attention of the local diabetes community; to translate global activities and objectives into a regional context; to support the work of IDF member associations and to strengthen the collaboration between these associations.
The seven IDF regions are:
1. Africa (AFR); 2. Europe (EUR); 3. Middle East and North Africa (MENA); 4. North America and Caribbean (NAC) 5. South and Central America (SACA); 6. South-East Asia (SEA); 7. Western Pacific (WP)
The mission of IDF is to advance diabetes care, prevention and a cure worldwide.
The strategic goals are to:
Further information about the International Diabetes Federation can be found at:http://www.idf.org
The International Alliance of Patients’ Organization (IAPO) is a unique global alliance representing patients of all nationalities across all disease areas and promoting patient-centred healthcare around the world. Our full members are patients’ organizations working at the international, regional, national and local levels to represent and support patients, their families and carers.
IAPO brings a global patient voice to healthcare decision-making based on the belief that patients’ voices are amplified and heard effectively when patient groups are linked, can share best practices and practical strategies and are connected with resources.
IAPO works within a global context on healthcare policy issues that cross geographical and disease boundaries such as access to health and health information, the quality and safety of healthcare and the engagement of patients in decisions that affect their lives.
IAPO is an international NGO, registered as an Association in The Netherlands (No. 30201854) and has its base in London, UK.
IAPO’s vision is that patients throughout the world are at the centre of healthcare.
IAPO helps build patient-centred healthcare worldwide by:
Further information about the International Alliance of Patients’ Organizations can be found at: http://www.patientsorganizations.org
The Steno Diabetes Center is an institution with more than 80 years of experience within diabetes care and prevention. Steno is owned by Novo Nordisk A/S and is a not for profit organisation working in partnership with the Danish healthcare system. Steno is organised in four centers that work closely together around the unifying focus of translational research, care and prevention:
1. Steno Research Center: the center is organised in three research groups: complications, epidemiology and pathophysiology.
2. Steno Health Promotion Center: the center is organised in two research units: Patient Education and Prevention.
3. Steno Patient Care Center: the center treats around 5,600 patients with type 1 and type 2 diabetes.
4. Steno Education Center: the center runs a wide range of educational activities nationally and internationally.
The challenges posed by pandemic diabetes, pandemic obesity and the related health care costs are well established and constitute a major public health crisis. To address the global diabetes epidemic, the 2020 strategy for Steno Diabetes Center strengthens the Center’s focus on the prevention and care of diabetes.
The Steno Diabetes Center’s vision is to become a global leader in translational diabetes research and clinical care with a focus on early disease and prevention to find solutions that will make a real difference for people with diabetes and those who are at risk of developing the condition.
The involvement in the DAWN2™ initiative is anchored within the Steno Health Promotion Center.
Further information about the Steno Diabetes Center can be found at:http://www.stenodiabetescenter.com